Effect of eltenac in horses with induced endotoxaemia.
Ten horses were used in a crossover study to evaluate the effectiveness of eltenac against endotoxaemia. Eltenac (0.5 mg/kg bwt) or saline control was given i.v. then 15 min later, intravenous infusion of endotoxin was begun and continued for 120 min (total dose 100 ng/kg bwt). Horses were monitored for heart and respiratory rates, pulmonary and carotid arterial pressure and core body temperature. Blood was sampled at intervals for measurement of haematological variables and plasma concentrations of lactate, prostanoid metabolites, tumour necrosis factor (TNF) and stress hormones. In comparison with saline-treatment, use of eltenac significantly protected against endotoxin-induced changes in respiratory rate, core temperature, systemic arterial blood pressure (SAP), pulmonary arterial pressure, PCV, and plasma protein, 6-keto prostaglandin F1 alpha, thromboxane B2, epinephrine, and cortisol concentrations. Despite statistical effect of eltenac on SAP, values in both treatment groups remained well above baseline throughout the evaluation period. Significant protective effect of eltenac was not found for heart rate, white blood cell count, plasma lactate concentration or TNF activity. On the basis of these results, it is expected that use of eltenac will provide clinical benefit in horses with naturally occurring endotoxaemia.
MacKay
R J
RJ
Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida 32610, USA.
Daniels
C A
CA
Bleyaert
H F
HF
Bailey
J E
JE
Gillis
K D
KD
Merritt
A M
AM
Katz
T L
TL
Johnson
J C
JC
Thompson
K C
KC
D000814:Aniline Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001427:Bacterial Toxins; D018592:Cross-Over Studies; D019446:Endotoxemia / Q000517:prevention & control / Q000662:veterinary*; D004927:Escherichia coli Infections / Q000517:prevention & control / Q000662:veterinary*; D006734:Horse Diseases / Q000097:blood / Q000517:prevention & control*; D006736:Horses; D007275:Injections, Intravenous / Q000662:veterinary; D010949:Plasma / Q000187:drug effects; D011453:Prostaglandins / Q000097:blood; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D011897:Random Allocation; D012119:Respiration / Q000187:drug effects; D013876:Thiophenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood
D000814:Aniline Compounds; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001427:Bacterial Toxins; D011453:Prostaglandins; D013876:Thiophenes; D013929:Thromboxane B2; C071200:eltenac